logo-loader
efyian

efyian raising $1mln to refine its chlamydia & gonorrhea diagnostic device

efyian CEO Angelika Niemz updates Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

efyian’s goal is to improve patient health through rapid accurate infectious disease diagnosis at the point of care via molecular diagnostic testing devices. The company is developing a molecular diagnostic device that allows doctors to receive accurate results right away in their office.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks flat but Valens shares on the rise as it...

Buds today are Valens GroWorks Corp (CVE:VGW) (OTCMKTS:VGWCF), The Flowr Corporation (CVE:FLWR) (OTCMKTS:FLWPF).  Duds are CannTrust Holdings Inc (TSE:TRST) (NYSE:CTST), Canopy Growth Corporation (TSE:WEED) (NYSE:CGC). 

25 minutes ago

2 min read